Table 1 Clinical application of CTCs in GC

Retrospective study

2 CTCs

116 patients with GC

85.3

90.3

0.928

Distinguish between GC patients and healthy controls and provide clinical thresholds

[27]

Number of CTCs

20 studies

42

99

0.97

Differentiate between GC patients and healthy controls

[28]

Single CTCs

24 patients with metastatic GC receiving chemotherapy

96

^a

^a

Detection of metastasis and drug resistance in GC

[29]

CTCs/DTCs

26 studies

^a

^a

^a

As the basis for GC staging

[30]

CSV + PD-L1 + CTCs

70 patients with GC

71

^a

^a

Predicts treatment response and prognosis in GC patients

[31]

CTC-PD-L1

32 patients with progressive GC

^a

^a

^a

Monitor prognosis and guide future individualized immunotherapy

[32]

Prospective study

CTCs and TWIST

32 patients with metastatic GC

80.6

^a

^a

As a prognostic marker

[33]

4 CTCs

52 patients with progressive GC

^a

^a

^a

As a surrogate marker for the efficacy of treatment with S-1 or paclitaxel in AGC patients

[34]

5 CTCs

65 treatment^anegative gastric adenocarcinomas

^a

^a

^a

Monitoring the prognosis and recurrence of GC

[35]

2 CTCs

44 patients with gastrointestinal tumors

69.9

^a

^a

Determining the prognosis of metastatic GC

[36]

FR + CTCs

132 patients with GC

77.8

54.5

0.68

Preoperative testing of FR + CTC levels helps predict PM and early recurrence in GC patients

[37]

CTCs/cfDNA

45 patients with progressive GC

95.6

^a

^a

Predicting the efficacy and prognosis of neoadjuvant chemotherapy for progressive GC

[38]